Wegovy, a weight loss medication developed by Novo Nordisk, is poised to become available in Australia in the near future. The Therapeutic Goods Administration (TGA) registered Wegovy in early 2025 for chronic weight management in adults, marking a significant advancement in obesity treatment options within the country.
In January 2026, the Pharmaceutical Benefits Advisory Committee (PBAC) recommended listing Wegovy on the Pharmaceutical Benefits Scheme (PBS) for patients with severe obesity and established cardiovascular disease. This recommendation is currently under negotiation, with a PBS listing expected no earlier than late 2026 or early 2027.
Wegovy is a glucagon-like peptide-1 (GLP-1) receptor agonist, similar to Ozempic, but administered at a higher dose of 2.4 mg weekly. Clinical trials have demonstrated that Wegovy can lead to an average weight loss of approximately 15–17% over 68–72 weeks.
As of mid-2026, Wegovy is available in Australia via private prescription, with costs ranging from $350 to $460 per month. The PBS subsidy, once implemented, is expected to significantly reduce the financial burden on patients, making the medication more accessible to those in need.
The anticipated launch of Wegovy in Australia represents a promising development in the fight against obesity, offering a new tool for individuals struggling with weight management and associated health risks.
In the United States, Novo Nordisk introduced an oral version of Wegovy in January 2026, providing an alternative to the injectable form. However, as of mid-2026, the oral pill has not been approved for use in Australia.
The global landscape for weight loss medications is evolving rapidly, with various companies developing and seeking approval for new treatments. The introduction of Wegovy in Australia is part of this broader trend, reflecting a growing recognition of the need for effective weight management solutions.
As the situation develops, it is crucial for healthcare professionals and patients to stay informed about the availability and regulatory status of weight loss medications to make well-informed decisions regarding treatment options.
For more detailed information on Wegovy's availability and access in Australia, individuals are encouraged to consult healthcare providers or visit official health department resources.